April 29, 2024
FDA approves Ractigen Therapeutics’ RAG-01 IND for bladder cancer
Ractigen Therapeutics has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for saRNA therapy RAG-01.